Lutetium Lu-177
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Lutetium Lu-177
- DrugBank Accession Number
- DB13982
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 176.9438
Monoisotopic: 176.943754987 - Chemical Formula
- Lu
- Synonyms
- 177Lu
- Lu 177
- Lu-177
- Lutetium-177
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Diagnostic agent Neuroendocrine tumour •••••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Lutetium chloride Lu-177 1U477369SN 16434-14-3 AEDROEGYZIARPU-SUNKFXMWSA-K - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Endolucinbeta 40 GBq/mL Itm Medical Isotopes Gmb H 2016-09-08 Not applicable EU Endolucinbeta 40 GBq/mL Itm Medical Isotopes Gmb H 2016-09-08 Not applicable EU Illuzyce 51.8 GBq/ml Billev Pharma Aps 2022-12-05 Not applicable EU Illuzyce 51.8 GBq/ml Billev Pharma Aps 2022-12-05 Not applicable EU Illuzyce 51.8 GBq/ml Billev Pharma Aps 2022-12-05 Not applicable EU
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as homogeneous lanthanide compounds. These are inorganic compounds containing only metal atoms, with the largest atom being a lanthanide atom.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous metal compounds
- Class
- Homogeneous lanthanide compounds
- Sub Class
- Not Available
- Direct Parent
- Homogeneous lanthanide compounds
- Alternative Parents
- Not Available
- Substituents
- Homogeneous lanthanide
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- BRH40Y9V1Q
- CAS number
- 14265-75-9
- InChI Key
- OHSVLFRHMCKCQY-NJFSPNSNSA-N
- InChI
- InChI=1S/Lu/i1+2
- IUPAC Name
- (177Lu)lutetium
- SMILES
- [177Lu]
References
- General References
- Not Available
- External Links
- ChemSpider
- 141480
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Not Yet Recruiting Treatment Castration-Resistant Prostate Carcinoma / Stage IVB Prostate Cancer AJCC v8 1 4 Recruiting Other Prostate Cancer 1 3 Active Not Recruiting Treatment Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 3 Active Not Recruiting Treatment Neuroendocrine Tumors 1 3 Not Yet Recruiting Treatment Neuroendocrine Tumors 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravenous 40 GBq/ml Solution Other 40 GBq/ml Solution Other 80 GBq/ml Solution Intravenous 80 GBg/mL Solution Intravenous 97 GBq Solution 40 GBq/ml Solution Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 0 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at January 20, 2018 19:24 / Updated at February 13, 2021 11:02